Google Scholar: citations
Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer
Wang, Kang (Karolinska University Hospital and Karolinska Institutet (Suècia))
Li, Lun (Fudan University)
Franch-Expósito, Sebastià (Hospital Clínic i Provincial de Barcelona)
Le, Xin (Chongqing University)
Tang, Jun (Chongqing University)
Li, Qing (Chongqing University)
Wu, Qianxue (Chongqing University)
Bassaganyas, Laia (Universitat de Barcelona)
Camps Polo, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Zhang, Xiang (Chongqing University)
Li, Hongyuan (Chongqing University)
Foukakis, Theodoros (Karolinska University Hospital and Karolinska Institutet (Suècia))
Xiang, Tingxiu (The First Affiliated Hospital of Chongqing Medical University)
Wu, Jiong (Fudan University)
Ren, Guosheng (The First Affiliated Hospital of Chongqing Medical University)

Date: 2021
Abstract: Estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER + HER2 -) breast cancer accounts for ~ 60-70% of all cases of invasive breast carcinoma. High-grade ER + HER2 - tumors respond poorly to endocrine therapy. In this study, we systematically analyzed clinical and multi-omics data to find potential strategies for personalized therapy of patients with high-grade ER + HER2 - disease. Six different cohorts were analyzed, for which multi-omics data were available. Grade III ER + HER2 - cases harbored higher proportions of large tumor size (.
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès
Document: Article ; recerca ; Versió publicada
Subject: Endocrine-resistant subgroup ; ER + HER2 - breast cancer ; Histologic grade ; Hypomethylated loci ; Multi-omics
Published in: Molecular oncology, Vol. 16 (july 2021) , p. 2413-2431, ISSN 1878-0261

DOI: 10.1002/1878-0261.13043
PMID: 34146382


19 p, 4.2 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles

 Record created 2024-05-30, last modified 2025-12-01



   Favorit i Compartir